安大略省耐药菌血症负担:110种病原-抗生素组合归因死亡的人群分析
BACKGROUND: Reliable information on the burden of antimicrobial resistance (AMR) is necessary to confront the threat of antimicrobial resistance.…
要点
- 未调整耐药与30天死亡HR为1.47(95%CI 1.32-1.65)。
- 调整后HR为1.10(95%CI 1.07-1.16),归因死亡每年每10万人1.2例。
核心结论
- 耐药与菌血症患者死亡风险相对增加10%相关,安大略省归因死亡为每年每10万人1.2例。
- 全面风险调整对于理解耐药菌血症对患者结局的影响是必要的。
研究设计与样本
- 使用114家医院、社区和公共卫生实验室的链接微生物学数据构建阳性细菌血培养发作队列。
- 纳入在病原培养中检测率>10%且耐药率1%-99%的抗生素,对每种病原分别建立比例风险模型,调整患者风险因素后用混合效应荟萃分析汇总。
主要发现
- 未调整的耐药与30天死亡关联(HR 1.47;95%CI 1.32-1.65)大于调整年龄、性别、医疗暴露、合并症和共耐药后的关联(HR 1.10;95%CI 1.07-1.16)。
- 常用于经验性治疗的抗生素,其关联更大(HR 1.18;95%CI 1.10-1.26)。
关键数值与推荐
- 抗生素纳入标准:在病原培养中检测率>10%且耐药率1%-99%。
- 未调整耐药与30天死亡HR 1.47(95%CI 1.32-1.65)。
- 调整后耐药与30天死亡HR 1.10(95%CI 1.07-1.16)。
- 经验性治疗常用抗生素的调整后HR 1.18(95%CI 1.10-1.26)。
- 归因死亡为每年每10万人1.2例。
临床怎么用
- 耐药与菌血症患者30天死亡风险相对增加10%相关,经验性治疗常用抗生素的关联更大(HR 1.18;95%CI 1.10-1.26)。
- 理解耐药菌血症对患者结局的影响需要全面的风险调整。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Reliable information on the burden of antimicrobial resistance (AMR) is necessary to confront the threat of antimicrobial resistance. We sought to examine the association between AMR and mortality across cultured bacterial bloodstream pathogens in the province of Ontario, Canada. METHODS: We used linked microbiology data from 114 hospital, community, and public health laboratories to develop a positive bacterial blood culture episode cohort, between January 2017 and December 2021, for the population of Ontario, Canada (population 14.6 million). Antibiotics tested in >10% of cultures of a pathogen, with resistance 1%-99%, were eligible. We used separate proportional hazards models for each pathogen, to estimate the hazard ratio of 30-day mortality for each eligible antibiotic, adjusting for patient risk factors, and summarized results using mixed-effects meta-analysis. RESULTS: We identified 83 962 bacteremia episodes, due to 30 pathogens, and 110 eligible pathogen-antibiotic combinations. The 30-day mortality was 17.1% (14 362/83 962). Unadjusted associations between resistance and 30-day mortality were substantially larger (hazard ratio [HR] = 1.47; 95% confidence interval [CI], 1.32-1.65) than adjusted associations accounting for age, sex, healthcare exposures, comorbidities, and co-resistance (HR = 1.10; 95% CI, 1.07-1.16). Associations were larger for antibiotics commonly used for empiric treatment (HR = 1.18; 95% CI, 1.10-1.26). CONCLUSIONS: We found that antimicrobial resistance was associated with a 10% relative increase in the risk of mortality among patients with bacteremia, and 1.2 AMR attributable deaths per 100 000 population per year in Ontario, Canada. Comprehensive risk adjustment is necessary for understanding the impact of AMR bacteremia on patient outcomes.
引用
- Brown KA, Fridman DJ, Garber GE, et al. The Burden of Antimicrobial Resistant Bacteremia in Ontario: A Population-Wide Analysis of Attributable Mortality From 110 Pathogen-Antibiotic Combinations. Clin Infect Dis. 2025. PMID: 40356393. doi:10.1093/cid/ciaf213
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。